Архитектура Аудит Военная наука Иностранные языки Медицина Металлургия Метрология
Образование Политология Производство Психология Стандартизация Технологии


Особенности ведения беременных с острым миелобластным лейкозом



При диагностике острого миелобластного лейкоза в первый триместр беременности до начала химиотерапии рекомендуется обсудить вопрос о прерывании беременности совместно гематологами и акушер-гинекологами.

При выявлении острого миелобластного лейкоза позже, после 12 недель беременности, во втором триместре, когда появляется гемато-плацентарный барьер для лекарственных препаратов, рекомендуется проведение химиотерапии в полном объеме, за исключением курсов HAM и FLAGIda, поскольку идарубицин и цитарабин в высоких дозах могут проникать через гематоплацентарный барьер.

Литература

1. Huang XJ, Zhu HH, Chang YJ, Xu LP, Liu DH, Zhang XH The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission Blood. 2012 Jun 7; 119(23): 5584-90.

2. Dö hner H, Estey EH, Amadori S, Appelbaum FR, Bü chner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood. 2010 Jan 21; 115(3): 453-74.

3. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM et al. Anthracycline dose intensification in acute myeloid leukemia N Engl J Med. 2009 Sep 24; 361(13): 1249-59.

4. Lö wenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A et al. High-dose daunorubicin in older patients with acute myeloid leukemia N Engl J Med. 2009 Sep 24; 361(13): 1235-48.

5. Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G at al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10 J Clin Oncol. 2009 Nov 10; 27(32): 5397-403.

6. Huang XJ, Zhu HH, Chang YJ, Xu LP, Liu DH, Zhang XH The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission Blood. 2012 Jun 7; 119(23): 5584-90.

7. Dö hner H, Estey EH, Amadori S, Appelbaum FR, Bü chner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood. 2010 Jan 21; 115(3): 453-74.

8. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM et al. Anthracycline dose intensification in acute myeloid leukemia N Engl J Med. 2009 Sep 24; 361(13): 1249-59.

9. Lö wenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A et al. High-dose daunorubicin in older patients with acute myeloid leukemia N Engl J Med. 2009 Sep 24; 361(13): 1235-48.

10. Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G at al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10 J Clin Oncol. 2009 Nov 10; 27(32): 5397-403.

11. ПаровичниковаЕ. Н., КлясоваГ. А., СоколовА. Н., ТроицкаяВ. В., КохноА. В., Кузьмина Л. А. Первые результаты лечения острых миелоидных лейкозов взрослых по протоколу ОМЛ-01.10 Научно-исследовательской группы гематологических центров России Терапевтический архив. 2012; 84(7): 10-5.

12. Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment Curr Cardiol Rev. 2011 Nov; 7(4): 214-20.

13. Estey E, Do¨ hner H. Acute myeloid leukaemia.Lancet. 2006; 368(9550): 1894-1907.

14. Estey EH. Growth factors in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001; 14(1): 175-187.

15. Lo¨ wenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003; 349(8): 743-752.

16. Thomas X, Raffoux E, de Botton S, et al. Effect of priming with granulocyte-macrophage colonystimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia. 2007; 21(3): 453-461.

17. Bu¨ chner T, Berdel WE, Hiddemann W. Priming with granulocyte colony stimulating factor – relation to high-dose cytarabine in acute myeloid leukemia comment. N Engl J Med. 2004; 350(21): 2215-2216.

18. Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood. 2002; 100(12): 3869-3876.

19. Gardin C, Turlure P, Fagot T, et al. Post-remission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007; 109(12): 5129-5135.

20. Burnett AK, Milligan D, Prentice AG, et al.: A comparison of lowdose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007; 109: 1114–24.

21. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998; 58(18): 4173-4179.

22. Elonen E, Almqvist A, Ha¨ nninen A, et al. Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group. Leukemia. 1998; 12(7): 1041-1048.

23. Burnett AK, Goldstone AH, Stevens RMF, et al. Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet. 1998; 351(9104): 700-708.

24. Moore JO, George SL, Dodge RK, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as post-remission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B study 9222. Blood. 2005; 105(9): 3420-3427.

25. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009; 301(22): 2349-2361.

26. Hengeveld M, Suciu S, Karrasch M, Specchia G, Marie JP, Muus P, Petti MC et al. Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups Ann Hematol. 2012 Jun; 91(6): 825-35.

27. Cornelissen JJ, van Putten WLJ, Verdonck LF, et al. Results of a HOVON/SAKK donor versus nodonor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middleaged adults: benefits for whom? Blood. 2007; 109(9): 3658-3666.

28. Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study Cancer. 2005 Dec 15; 104(12): 2726-34.

29. Bü chner T, Schlenk RF, Schaich M, Dö hner K, Krahl R, Krauter J Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm--Combined Prospective Analysis by the German AML Intergroup J Clin Oncol. 2012 Oct 10; 30(29): 3604-10.

30. Elonen E, Almqvist A, Hanninen A, et al. Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group. Leukemia. 1998; 12: 1041-1048.

31. Morra E, Barosi G, Bosi A, Ferrara F, Locatelli F, Marchetti M, Martinelli G, Mecucci C, Vignetti M, Tura S. Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation Haematologica. 2009 Jan; 94(1): 102-12.

32. Usuki K, Kurosawa S, Uchida N, Yakushiji K, Waki F, Matsuishi E et al. Comparison of Autologous Hematopoietic Cell Transplantation and Chemotherapy as Postremission Treatment in Non-M3 Acute Myeloid Leukemia in First Complete Remission Clin Lymphoma Myeloma Leuk. 2012 Sep 19.pii: S2152-2650.

33. Pfirrmann M, Ehninger G, Thiede C, Bornhä user M, Kramer M, Rö llig C, Hasford J, Schaich M Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial Lancet Oncol. 2012 Feb; 13(2): 207-14.

34. Buchner T, Hiddemann W, Berdei W, et al. 6-thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML). A randomized trial of the German AML Cooperative Group.J Clin Oncol. 2003; 21: 4496-4504.

35. Hewlett J, Kopecky K, Head D, et al. A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML).A Southwest Oncology Group Study.Leukemia. 1995; 9: 562-569.

36. Bü chner T, Hiddemann W, Wö rmann B, Lö ffler H, Ludwig WD, Schoch C Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary? Int J Hematol. 2000 Oct; 72(3): 285-9.

37. Pfirrmann M, Ehninger G, Thiede C, Bornhä user M, Kramer M, Rö llig C, Hasford J, and Schaich M, for the Study Alliance Leukaemia (SAL). Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol. 2012 Feb; 13(2): 207-214.

38. Fung HC, Stein A, Slovak ML, et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant. 2003; 9(12): 766-771.

39. Breems DA, Van Putten WLJ, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005; 23(9): 1969-1978.

40. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.Blood. 1996; 87(5): 1710-1717.

41. Herzig RH, Lazarus HM, Wolff SN, Phillips GL, Herzig GP. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.J Clin Oncol. 1985; 3(7): 992-997.

42. Daenen S, Lo¨ wenberg B, Sonneveld P, et al. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediatedose cytarabine with amsidine. Leukemia. 1994; 8(1): 6-10.

43. NCCN guidelines Version 1/2012 Hrevention and treatment of Cancer-Related Infection (INF-1 –FEV-9; FEV-11 – FEV-F)

44. http: //www.chemoregimen.com/


 


Поделиться:



Последнее изменение этой страницы: 2017-03-17; Просмотров: 617; Нарушение авторского права страницы


lektsia.com 2007 - 2024 год. Все материалы представленные на сайте исключительно с целью ознакомления читателями и не преследуют коммерческих целей или нарушение авторских прав! (0.023 с.)
Главная | Случайная страница | Обратная связь